Common Contracts
6 similar Employment Agreement contracts by Blueprint Medicines Corp
EMPLOYMENT AGREEMENTEmployment Agreement • November 22nd, 2017 • Blueprint Medicines Corp • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is dated as of November 22, 2017 (the “Effective Date”), between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Michael Landsittel (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 31st, 2017 • Blueprint Medicines Corp • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is dated as of October 10, 2017 (the “Effective Date”), between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Chris Murray (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 11th, 2016 • Blueprint Medicines Corp • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is dated as of March 10, 2016 (the “Effective Date”), between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Kathryn Haviland (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 9th, 2015 • Blueprint Medicines Corp • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is dated as of November 6, 2015 (the “Effective Date”), between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Christoph Lengauer (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 9th, 2015 • Blueprint Medicines Corp • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is dated as of November 6, 2015 (the “Effective Date”), between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Anthony L. Boral (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 9th, 2015 • Blueprint Medicines Corp • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is dated as of November 6, 2015 (the “Effective Date”), between Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Jeffrey W. Albers (the “Executive”).
